Will Apple’s ResearchKit Change Science?

The technology company is launching a new data-sharing platform that it says can make any iPhone user a medical research participant. But the associated ethics are anything but simple.

Written byBob Grant
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

WIKIMEDIA, ZAREXApple this week (March 9) announced plans to launch a new medical research data-sharing platform called ResearchKit. The platform will be available to researchers conducting large-scale medical studies, and iPhone apps will allow users to share their health data with those scientists, in theory making it much easier to recruit and track study participants. “There are hundreds of millions of iPhone owners out there who would gladly contribute,” said Jeff Williams, Apple’s senior vice president of operations, during the event announcing ResearchKit.

At the event, Apple also released five disease-specific apps built using ResearchKit. They can be used to study asthma, breast cancer, cardiovascular health, diabetes, and Parkinson’s disease. “The ResearchKit framework offers the ability to track disease signs by sensors that are on the phone or the Apple watch, or on third-party devices,” Stephen Friend, president of Apple partner Sage Bionetworks, told Nature. “Symptoms can also be tracked by people filling out survey information on themselves.”

Williams noted that Apple will not have access to user data, but some in the research community are warning that the simplified study recruitment that ResearchKit may facilitate could raise ethical quandaries for researchers using the platform. These include ensuring that participants knowledgeable of the risks involved with participating in ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies